Restricted accessResearch articleFirst published online 2018-01
Human Wharton's Jelly-Derived Stem Cells Display a Distinct Immunomodulatory and Proregenerative Transcriptional Signature Compared to Bone Marrow-Derived Stem Cells
Mesenchymal stromal cells (MSCs) are multipotent stem cells with immunosuppressive and trophic support functions. While MSCs from different sources frequently display a similar appearance in culture, they often show differences in their surface marker and gene expression profiles. Although bone marrow is considered the “gold standard” tissue to isolate classical MSCs (BM-MSC), MSC-like cells are currently also derived from more easily accessible extra-embryonic tissues such as the umbilical cord. In this study, we defined the best way to isolate MSCs from the Wharton's jelly of the human umbilical cord (WJ-MSC) and assessed the mesenchymal and immunological phenotype of BM-MSC and WJ-MSC. Moreover, the gene expression profile of established WJ-MSC cultures was compared to two different bone marrow-derived stem cell populations (BM-MSC and multipotent adult progenitor cells or MAPC®). We observed that explant culturing of Wharton's jelly matrix is superior to collagenase tissue digestion for obtaining mesenchymal-like cells, with explant isolated cells displaying increased expansion potential. While being phenotypically similar to adult MSCs, WJ-MSC show a different gene expression profile. Gene ontology analysis revealed that genes associated with cell adhesion, proliferation, and immune system functioning are enriched in WJ-MSC. In vivo transplantation confirms their immune modulatory effect on T cells, similar to BM-MSC and MAPC. Furthermore, WJ-MSC intrinsically overexpress genes involved in neurotrophic support and their secretome induces neuronal maturation of SH-SY5Y neuroblastoma cells to a greater extent than BM-MSC. This signature makes WJ-MSC an attractive candidate for cell-based therapy in neurodegenerative and immune-mediated central nervous system disorders such as multiple sclerosis, Parkinson's disease, or amyotrophic lateral sclerosis.
Get full access to this article
View all access options for this article.
References
1.
ProckopDJ. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 276:71–74.
2.
PittengerMF, MackayAM, BeckSC, JaiswalRK, DouglasR, MoscaJD, MoormanMA, SimonettiDW, CraigS and MarshakDR. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284:143–147.
3.
FriedensteinAJ, GorskajaJF and KulaginaNN. (1976). Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol, 4:267–274.
4.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
5.
GhannamS, BouffiC, DjouadF, JorgensenC and NoelD. (2010). Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther, 1:2.
YagiH, Soto-GutierrezA, ParekkadanB, KitagawaY, TompkinsRG, KobayashiN and YarmushML. (2010). Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant, 19:667–679.
8.
Le BlancK and RingdenO. (2007). Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med, 262:509–525.
9.
WexlerSA, DonaldsonC, Denning-KendallP, RiceC, BradleyB and HowsJM. (2003). Adult bone marrow is a rich source of human mesenchymal ‘stem’ cells but umbilical cord and mobilized adult blood are not. Br J Haematol, 121:368–374.
10.
BatsaliAK, KastrinakiMC, PapadakiHA and PontikoglouC. (2013). Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. Curr Stem Cell Res Ther, 8:144–155.
11.
SetheS, ScuttA and StolzingA. (2006). Aging of mesenchymal stem cells. Ageing Res Rev, 5:91–116.
12.
StenderupK, JustesenJ, ClausenC and KassemM. (2003). Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone, 33:919–926.
13.
KokaiLE, MarraK and RubinJP. (2014). Adipose stem cells: biology and clinical applications for tissue repair and regeneration. Transl Res, 163:399–408.
14.
KoninckxR, DanielsA, WindmoldersS, MeesU, MacianskieneR, MubagwaK, SteelsP, JamaerL, DuboisJ, et al. (2013). The cardiac atrial appendage stem cell: a new and promising candidate for myocardial repair. Cardiovasc Res, 97:413–423.
ParoliniO and CarusoM. (2011). Review: preclinical studies on placenta-derived cells and amniotic membrane: an update. Placenta, 32 (Suppl. 2):S186–S195.
17.
LindenmairA, HatlapatkaT, KollwigG, HennerbichlerS, GabrielC, WolbankS, RedlH and KasperC. (2012). Mesenchymal stem or stromal cells from amnion and umbilical cord tissue and their potential for clinical applications. Cells, 1:1061–1088.
18.
McGuckinCP and ForrazN. (2008). Potential for access to embryonic-like cells from human umbilical cord blood. Cell Prolif, 41 (Suppl. 1):31–40.
19.
MitchellKE, WeissML, MitchellBM, MartinP, DavisD, MoralesL, HelwigB, BeerenstrauchM, Abou-EasaK, et al. (2003). Matrix cells from Wharton's jelly form neurons and glia. Stem Cells, 21:50–60.
20.
WangHS, HungSC, PengST, HuangCC, WeiHM, GuoYJ, FuYS, LaiMC and ChenCC. (2004). Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells, 22:1330–1337.
21.
RomanovYA, SvintsitskayaVA and SmirnovVN. (2003). Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells, 21:105–110.
22.
WeissML, AndersonC, MedicettyS, SeshareddyKB, WeissRJ, VanderWerffI, TroyerD and McIntoshKR. (2008). Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells, 26:2865–2874.
23.
NajarM, RaicevicG, BoufkerHI, Fayyad-KazanH, De BruynC, MeulemanN, BronD, ToungouzM and LagneauxL. (2010). Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A, 16:3537–3546.
24.
BongsoA and FongCY. (2013). The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord. Stem Cell Rev, 9:226–240.
25.
DalousJ, LargheroJ and BaudO. (2012). Transplantation of umbilical cord-derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives. Pediatr Res, 71:482–490.
26.
TroyerDL and WeissML. (2008). Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells, 26:591–599.
27.
CanA and KarahuseyinogluS. (2007). Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells, 25:2886–2895.
28.
WeissML and TroyerDL. (2006). Stem cells in the umbilical cord. Stem Cell Rev, 2:155–162.
29.
PappaKI and AnagnouNP. (2009). Novel sources of fetal stem cells: where do they fit on the developmental continuum?. Regen Med, 4:423–433.
30.
BiancoP, CaoX, FrenettePS, MaoJJ, RobeyPG, SimmonsPJ and WangCY. (2013). The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med, 19:35–42.
31.
Dore-DuffyP. (2008). Pericytes: pluripotent cells of the blood brain barrier. Curr Pharm Des, 14:1581–1593.
32.
BlockiA, WangY, KochM, PehP, BeyerS, LawP, HuiJ and RaghunathM. (2013). Not all MSCs can act as pericytes: functional in vitro assays to distinguish pericytes from other mesenchymal stem cells in angiogenesis. Stem Cells Dev, 22:2347–2355.
33.
StruysT, MoreelsM, MartensW, DondersR, WolfsE and LambrichtsI. (2011). Ultrastructural and immunocytochemical analysis of multilineage differentiated human dental pulp- and umbilical cord-derived mesenchymal stem cells. Cells Tissues Organs, 193:366–378.
34.
HassR, KasperC, BohmS and JacobsR. (2011). Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal, 9:12.
35.
SchugarRC, ChirieleisonSM, WescoeKE, SchmidtBT, AskewY, NanceJJ, EvronJM, PeaultB and DeasyBM. (2009). High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. J Biomed Biotechnol, 2009:789526.
36.
R Core Team(2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
37.
GentlemanRC, CareyVJ, BatesDM, BolstadB, DettlingM, DudoitS, EllisB, GautierL, GeY, et al. (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol, 5:R80.
38.
CarvalhoBS and IrizarryRA. (2010). A framework for oligonucleotide microarray preprocessing. Bioinformatics, 26:2363–2367.
39.
SmythGK. (2005). Limma: linear models for microarray data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. GentlemanR, CareyV, HuberW, IrizarryR and DudoitS eds. Springer, New York. pp 397–420.
40.
PlonerA. (2015). Heatplus: Heatmaps with row and/or column covariates and colored clusters. R package version 2.24.0, https://github.com/alexploner/Heatplus.
41.
GentlemanR, CareyV, HuberW and Hahne.F (2014). Genefilter: methods for filtering genes from microarray experiments. R package version 1.46.1.
42.
Huang daW, ShermanBT and LempickiRA. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 4:44–57.
43.
Huang daW, ShermanBT and LempickiRA. (2009). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res, 37:1–13.
44.
BogieJF, TimmermansS, Huynh-ThuVA, IrrthumA, SmeetsHJ, GustafssonJA, SteffensenKR, MulderM, StinissenP, HellingsN and HendriksJJ. (2012). Myelin-derived lipids modulate macrophage activity by liver X receptor activation. PLoS One, 7:e44998.
45.
EdgarR, DomrachevM and LashAE. (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res, 30:207–210.
46.
EncinasM, IglesiasM, LiuY, WangH, MuhaisenA, CenaV, GallegoC and ComellaJX. (2000). Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem, 75:991–1003.
47.
GervoisP, WolfsE, DillenY, HilkensP, RatajczakJ, DriesenRB, VangansewinkelT, BronckaersA, BroneB, StruysT and LambrichtsI. (2017). Paracrine maturation and migration of SH-SY5Y cells by dental pulp stem cells. J Dent Res, 96:654–662.
48.
GervoisP, StruysT, HilkensP, BronckaersA, RatajczakJ, PolitisC, BroneB, LambrichtsI and MartensW. (2015). Neurogenic maturation of human dental pulp stem cells following neurosphere generation induces morphological and electrophysiological characteristics of functional neurons. Stem Cells Dev, 24:296–311.
49.
SchindelinJ, Arganda-CarrerasI, FriseE, KaynigV, LongairM, PietzschT, PreibischS, RuedenC, SaalfeldS, et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat Methods, 9:676–682.
50.
MeijeringE, JacobM, SarriaJC, SteinerP, HirlingH and UnserM. (2004). Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytometry A, 58:167–176.
51.
BogieJF, StinissenP, HellingsN and HendriksJJ. (2011). Myelin-phagocytosing macrophages modulate autoreactive T cell proliferation. J Neuroinflammation, 8:85.
52.
SeshareddyK, TroyerD and WeissML. (2008). Method to isolate mesenchymal-like cells from Wharton's Jelly of umbilical cord. Methods Cell Biol, 86:101–119.
53.
DondersR, VanheusdenM, BogieJF, RavanidisS, ThewissenK, StinissenP, GyselaersW, HendriksJJ and HellingsN. (2015). Human Wharton's jelly-derived stem cells display immunomodulatory properties and transiently improve rat experimental autoimmune encephalomyelitis. Cell Transplant, 24:2077–2098.
54.
CaplanAI. (2007). Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol, 213:341–347.
55.
SalehinejadP, AlitheenNB, AliAM, OmarAR, MohitM, JanzaminE, SamaniFS, TorshiziZ and Nematollahi-MahaniSN. (2012). Comparison of different methods for the isolation of mesenchymal stem cells from human umbilical cord Wharton's jelly. In Vitro Cell Dev Biol Anim, 48:75–83.
56.
CorotchiMC, PopaMA, RemesA, SimaLE, GussiI and Lupu PlesuM. (2013). Isolation method and xeno-free culture conditions influence multipotent differentiation capacity of human Wharton's jelly-derived mesenchymal stem cells. Stem Cell Res Ther, 4:81.
57.
Iftimia-ManderA, HourdP, DaintyR and ThomasRJ. (2013). Mesenchymal stem cell isolation from human umbilical cord tissue: understanding and minimizing variability in cell yield for process optimization. Biopreserv Biobank, 11:291–298.
58.
YoonJH, RohEY, ShinS, JungNH, SongEY, ChangJY, KimBJ and JeonHW. (2013). Comparison of explant-derived and enzymatic digestion-derived MSCs and the growth factors from Wharton's jelly. Biomed Res Int, 2013:428726.
59.
WagnerW, HornP, CastoldiM, DiehlmannA, BorkS, SaffrichR, BenesV, BlakeJ, PfisterS, EcksteinV and HoAD. (2008). Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One, 3:e2213.
60.
PogozhykhO, PogozhykhD, NeehusAL, HoffmannA, BlasczykR and MullerT. (2015). Molecular and cellular characteristics of human and non-human primate multipotent stromal cells from the amnion and bone marrow during long term culture. Stem Cell Res Ther, 6:150.
61.
De BruynC, NajarM, RaicevicG, MeulemanN, PietersK, StamatopoulosB, DelforgeA, BronD and LagneauxL. (2011). A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton's jelly without enzymatic treatment. Stem Cells Dev, 20:547–557.
62.
KimDW, StaplesM, ShinozukaK, PantchevaP, KangSD and BorlonganCV. (2013). Wharton's jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci, 14:11692–11712.
63.
FongCY, ChakLL, BiswasA, TanJH, GauthamanK, ChanWK and BongsoA. (2011). Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev, 7:1–16.
64.
HsiehJY, WangHW, ChangSJ, LiaoKH, LeeIH, LinWS, WuCH, LinWY and ChengSM. (2013). Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One, 8:e72604.
65.
De KockJ, NajarM, BolleynJ, Al BattahF, RodriguesRM, BuylK, RaicevicG, GovaereO, BransonS, et al. (2012). Mesoderm-derived stem cells: the link between the transcriptome and their differentiation potential. Stem Cells Dev, 21:3309–3323.
66.
JiangY, JahagirdarBN, ReinhardtRL, SchwartzRE, KeeneCD, Ortiz-GonzalezXR, ReyesM, LenvikT, LundT, et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 418:41–49.
67.
RavanidisS, BogieJF, DondersR, CraeyeD, MaysRW, DeansR, GijbelsK, BronckaersA, StinissenP, PinxterenJ and HellingsN. (2015). Neuroinflammatory signals enhance the immunomodulatory and neuroprotective properties of multipotent adult progenitor cells. Stem Cell Res Ther, 6:176.
68.
SubramanianK, GeraertsM, PauwelynKA, ParkY, OwensDJ, MuijtjensM, Ulloa-MontoyaF, JiangY, VerfaillieCM and HuWS. (2010). Isolation procedure and characterization of multipotent adult progenitor cells from rat bone marrow. Methods Mol Biol, 636:55–78.
69.
Ulloa-MontoyaF, KidderBL, PauwelynKA, ChaseLG, LuttunA, CrabbeA, GeraertsM, SharovAA, PiaoY, et al. (2007). Comparative transcriptome analysis of embryonic and adult stem cells with extended and limited differentiation capacity. Genome Biol, 8:R163.
70.
BoozerS, LehmanN, LakshmipathyU, LoveB, RaberA, MaitraA, DeansR, RaoMS and TingAE. (2009). Global characterization and genomic stability of human multistem, a multipotent adult progenitor cell. J Stem Cells, 4:17–28.
71.
BuschSA, HamiltonJA, HornKP, CuascutFX, CutroneR, LehmanN, DeansRJ, TingAE, MaysRW and SilverJ. (2011). Multipotent adult progenitor cells prevent macrophage-mediated axonal dieback and promote regrowth after spinal cord injury. J Neurosci, 31:944–953.
72.
BurrowsGG, Van't HofW, NewellLF, ReddyA, WilmarthPA, DavidLL, RaberA, BogaertsA, PinxterenJ, DeansRJ and MaziarzRT. (2013). Dissection of the human multipotent adult progenitor cell secretome by proteomic analysis. Stem Cells Transl Med, 2:745–757.
73.
La RoccaG, AnzaloneR, CorraoS, MagnoF, LoriaT, Lo IaconoM, Di StefanoA, GiannuzziP, MarasaL, et al. (2009). Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochem Cell Biol, 131:267–282.
74.
TeixeiraFG, CarvalhoMM, SousaN and SalgadoAJ. (2013). Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?. Cell Mol Life Sci, 70:3871–3882.
75.
PluchinoS, ZanottiL, BrambillaE, Rovere-QueriniP, CapobiancoA, Alfaro-CervelloC, SalaniG, CossettiC, BorsellinoG, et al. (2009). Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. PLoS One, 4:e5959.
76.
PayneNL, SunG, McDonaldC, LaytonD, MoussaL, Emerson-WebberA, VeronN, SiatskasC, HerszfeldD, PriceJ and BernardCC. (2013). Distinct immunomodulatory and migratory mechanisms underpin the therapeutic potential of human mesenchymal stem cells in autoimmune demyelination. Cell Transplant, 22:1409–1425.
77.
WyattS, AndresR, RohrerH and DaviesAM. (1999). Regulation of neurotrophin receptor expression by retinoic acid in mouse sympathetic neuroblasts. J Neurosci, 19:1062–1071.
78.
PiresAO, Neves-CarvalhoA, SousaN and SalgadoAJ. (2014). The secretome of bone marrow and wharton jelly derived mesenchymal stem cells induces differentiation and neurite outgrowth in SH-SY5Y Cells. Stem Cells Int, 2014:438352.
79.
ParkH and PooMM. (2013). Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci, 14:7–23.
80.
MartinsLF, CostaRO, PedroJR, AguiarP, SerraSC, TeixeiraFG, SousaN, SalgadoAJ and AlmeidaRD. (2017). Mesenchymal stem cells secretome-induced axonal outgrowth is mediated by BDNF. Sci Rep, 7:4153.
81.
CriglerL, RobeyRC, AsawachaicharnA, GauppD and PhinneyDG. (2006). Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol, 198:54–64.
82.
RibeiroCA, FragaJS, GraosM, NevesNM, ReisRL, GimbleJM, SousaN and SalgadoAJ. (2012). The secretome of stem cells isolated from the adipose tissue and Wharton jelly acts differently on central nervous system derived cell populations. Stem Cell Res Ther, 3:18.
83.
Joerger-MesserliM, SpinelliM, OppligerB, Di SalvoI, MuellerM, SchoeberleinA and Surbek.DV. 394: Neuro-protective and -regenerative effects of exosomes derived from Wharton's jelly mesenchymal stem cells. Am J Obstet Gynecol, 216:S236–S237.
84.
WeissML, MedicettyS, BledsoeAR, RachakatlaRS, ChoiM, MerchavS, LuoY, RaoMS, VelagaletiG and TroyerD. (2006). Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells, 24:781–792.
85.
KohSH, KimKS, ChoiMR, JungKH, ParkKS, ChaiYG, RohW, HwangSJ, KoHJ, et al. (2008). Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in rats. Brain Res, 1229:233–248.
86.
LinYC, KoTL, ShihYH, LinMY, FuTW, HsiaoHS, HsuJY and FuYS. (2011). Human umbilical mesenchymal stem cells promote recovery after ischemic stroke. Stroke, 42:2045–2053.
87.
YangCC, ShihYH, KoMH, HsuSY, ChengH and FuYS. (2008). Transplantation of human umbilical mesenchymal stem cells from Wharton's jelly after complete transection of the rat spinal cord. PLoS One, 3:e3336.
88.
CarvalhoMM, TeixeiraFG, ReisRL, SousaN and SalgadoAJ. (2011). Mesenchymal stem cells in the umbilical cord: phenotypic characterization, secretome and applications in central nervous system regenerative medicine. Curr Stem Cell Res Ther, 6:221–228.
89.
RoobrouckVD, VanuytselK and VerfaillieCM. (2011). Concise review: culture mediated changes in fate and/or potency of stem cells. Stem Cells, 29:583–589.
90.
RoobrouckVD, ClavelC, JacobsSA, Ulloa-MontoyaF, CrippaS, SohniA, RobertsSJ, LuytenFP, Van GoolSW, et al. (2011). Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells, 29:871–882.
91.
DelarosaO, DalemansW and LombardoE. (2012). Toll-like receptors as modulators of mesenchymal stem cells. Front Immunol, 3:182.
92.
GattaV, D'AuroraM, LanutiP, PierdomenicoL, SperdutiS, PalkaG, GesiM, MarchisioM, MisciaS and StuppiaL. (2013). Gene expression modifications in Wharton's Jelly mesenchymal stem cells promoted by prolonged in vitro culturing. BMC Genomics, 14:635.
93.
KlingemannH, MatzilevichD and MarchandJ. (2008). Mesenchymal Stem Cells - Sources and Clinical Applications. Transfus Med Hemother, 35:272–277.
94.
LeeKS, NahJJ, LeeBC, LeeHT, LeeHS, SoBJ and ChaSH. (2013). Maintenance and characterization of multipotent mesenchymal stem cells isolated from canine umbilical cord matrix by collagenase digestion. Res Vet Sci, 94:144–151.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
